Taken together, our study revealed evidence-based validation of echocardiographic variables to determine risk status and predict prognosis in patients with SSc-associated PAH and implied that the TAPSE/PASP ratio is potentially appropriate for further clinical applications in severity identification, treatment decision, prognosis prediction, and follow-up. This evidence concerns the gene CPB1 and pulmonary arterial hypertension.